Postoperative Efficacy of Erector Spinae Plane Block Versus Its Combination With Superficial Parasternal Intercostal Plane Block in Patients Undergoing CABG Surgery
Comparison Between Postoperative Efficacy of Erector Spinae Plane Block Versus Its Combination With Superficial Parasternal Intercostal Plane Block in Patients Undergoing CABG Surgery
The aim of this study was to compare Postoperative Efficacy of Erector Spinae Plane Block versus its Combination with Superficial Parasternal Intercostal Plane Block in Patients Undergoing coronary artery bypass grafting Surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
More than 800,000 coronary artery bypass grafting surgeries are performed worldwide every year. Post cardiac surgery, 30-75% of patients report moderate to severe acute pain. In the postoperative period, 4-10% of patients may develop chronic post-sternotomy pain syndrome.
In cardiac surgery, good postoperative pain management positively affects clinical outcomes. Although the pain is usually related to the sternotomy, rib or intercostal nerve injury, parietal pleura, pericardium, chest tube placement, and sternal retraction also contribute to postoperative pain.
Adequate analgesia provides hemodynamic stability, improved myocardial oxygenation, and immunological and hemostatic modulation, decreasing the duration of mechanical ventilation and reducing cardiac ischemic events and arrhythmias in the postoperative period. Improved pain control reduces surgery-related complications and has a significant impact on the duration of hospital stay and patient satisfaction. For this reason, adequate analgesia as well as intraoperative and postoperative anesthesia should be a high priority for intensive care teams.
Analgesia with serratus anterior plane block and pectoral muscle plane block, which are regional nerve blocks, do not cover midline sternotomy pain. On the other hand, even though intercostal block, infiltration block, and thoracic paravertebral block cover sternotomy pain, the rate of complications increases in these procedures as they require multiple injections and are performed close to pleura.
Alternatively, erector spinae plane block , provides multidermatomal sensory block when applied bilaterally at the target level and it can prevent somatic and visceral pain by affecting the dorsal and ventral rami regions of the spinal nerves. The block is applied by administering local anesthetic between the vertebral transverse process and the deep surface of the erector spinae muscle. Erector Spinae Plane Block may be used for postoperative analgesia in breast, thoracic, and lumbar surgeries as it is simple, reliable and effective. There are a limited number of studies in the literature regarding its use in patients undergoing cardiac surgery.
Superficial parasternal intercostal block , a facial block that provides analgesia in the parasternal area by blocking the anterior cutaneous branches of the thoracic intercostal nerves (T2-6). The S-PIP block may increase analgesic efficacy when combined with the Erector Spinae Plane block, as distribution is inconsistent with the Erector Spinae Plane Block block.
The aim of this study was to compare Postoperative Efficacy of Erector Spinae Plane Block versus its Combination with Superficial Parasternal Intercostal Plane Block in Patients Undergoing coronary artery bypass grafting Surgery.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain shams university
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients American Society of Anesthesiologists physical status III to IV.
- Both genders.
- Aged 40-80 years old.
- Scheduled for Coronary artery bypass grafting .
Exclusion Criteria:
- Patients with major spine deformities.
- Patients with bleeding disorders and coagulopathy.
- Infection at the injection site.
- Allergy to local anesthetics.
- Patients with pre-existing myopathy or neuropathy.
- Patients with significant cognitive dysfunction.
- Patients who received long acting opioids preoperatively.
- Patients with hepatic or renal failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group E
Group E : patients received ultrasound guided ESP block with 0.25% bupivacaine before sternotomy. |
Group E : patients received ultrasound guided Erector Spinae Plane Block block with 0.25% bupivacaine before stern |
|
Experimental: Group EP
Group EP : patients received ultrasound guided Erector Spinae Plane Block and Superficial Parasternal Intercostal Plane Block with 0.25% bupivacaine before sternotomy. |
Group EP : patients received ultrasound guided Erector Spinae Plane Block and Superficial Parasternal Intercostal Plane Block with 0.25% bupivacaine before sternotomy. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
compare the pain score between the two groups postoperatively by visual analogue scale
Time Frame: at PACU, 2 hours,4 hours, 6 hours, 12 hours, 18 hours, and 24 hours
|
Visual Analog Scale (VAS) is a subjective diagnostic tool used to measure the intensity of pain or other symptoms along a continuous line. It typically features a horizontal line exactly 100 millimeters (10 cm) in length, anchored by two verbal extremes, such as "no pain" on the far left and "worst imaginable pain" on the far right. |
at PACU, 2 hours,4 hours, 6 hours, 12 hours, 18 hours, and 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
postoperative opioid consumption
Time Frame: at 24 hours
|
at 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- FMASU R216 /2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
It will be available if it needed
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.